Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 AK001 in moderate to severe nasal polyposis
NL-OMON42893Phase 2Active, not recruiting
- Sponsor
- MediServ
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AK001 in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by MediServ. Primary endpoint: Change in Total Polyp Score. Started Sep 2016; status: active, not recruiting.
02
Drugs
AK001
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NL-OMON42893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42893.